Enjoy complimentary customisation on priority with our Enterprise License!
The multiple sclerosis market share in US is expected to increase by USD 3.95 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.83%.
This multiple sclerosis market in US research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers multiple sclerosis market segmentation in US by type (biologics and small molecules) and route of administration (parenteral and oral). The multiple sclerosis market in US report also offers information on several market vendors, including Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Multiple Sclerosis Market Size in US for the Forecast Period and Other Important Statistics
The strong pipeline is notably driving the multiple sclerosis market growth in US, although factors such as high cost of drugs may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the multiple sclerosis industry in US. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Multiple Sclerosis Market Driver in US
One of the key factors driving growth in the multiple sclerosis market is the strong pipeline. Several players are expanding their research to develop new formulations of the existing drugs for multiple sclerosis (MS) due to the significant unmet demand in the market. The high prevalence of the disease, the considerable cost burden on patients, and the lack of effective treatments are encouraging vendors to conduct advanced research on MS to launch better therapeutics in the market to treat the disease. The ongoing R&D of new drugs is resulting in a strong drug pipeline for the treatment of MS. Therefore, the increasing clinical trials of MS drugs will drive market growth during the forecast period.
Key Multiple Sclerosis Market Trend in US
The rising strategic alliance and partnership among vendors is another factor supporting the multiple sclerosis market share growth. Vendors in the market are forming strategic partnerships and acquiring vendors for product development. For instance, in 2021, Biogen announced its license and collaboration agreement with InnoCare Pharma for orelabrutinib, a small oral molecule of Bruton's tyrosine kinase inhibitor (BTKi) for treating MS patients. The partnership will allow Biogen to expand its MS pipeline portfolio with a promising treatment. Similarly, in 2020, Mapi Pharma and Mylan strengthened their partnership for developing and commercializing the injection of Glatiramer Acetate Depot monthly once. Mylan invested $20 million in support of a continued Phase III clinical study to bring Glatiramer Acetate (GA) Depot into the US market.
Key Multiple Sclerosis Market Challenge in US
The high cost of drugs will be a major challenge for the multiple sclerosis market during the forecast period. MS is an autoimmune disease where the person's own immune cells start attacking the central nervous system . The immune system attacks the protective sheath (myelin) that covers nerve fibers and impacts communication between the brain and the rest of the body. Signs and symptoms may differ greatly from person to person and over the course of the disease, depending on the location of affected nerve fibers. Treatments can help speed recovery and modify the course of the disease, and manage symptoms. However, the lifetime cost per MS patient is over $4 million in the US. The annual costs of MS in the first and second lines of drug therapy per patient were $1,919 and $4,082, respectively, and in total, $2,721 in 2019. Patients thus struggle to meet the cost of treatment of MS in the US. This is the major challenge for the market, which will hamper the growth.
This multiple sclerosis market in US analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the multiple sclerosis market in US as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the multiple sclerosis market in US during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the multiple sclerosis market in US encompasses successful business strategies deployed by the key vendors. The multiple sclerosis market in US is fragmented and the vendors are deploying growth strategies such as forming strategic partnerships for product development and expanding their pipeline portfolio to compete in the market.
F. Hoffmann La Roche Ltd. - The company offers solutions for multiple sclerosis that targets a type of immune cell called the CD20-positive B cell that plays a key role in the disease, under the brand name of Ocrevus.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The multiple sclerosis market in US forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the multiple sclerosis market in US, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 06: Parent market
*Exhibit 07: Market Characteristics
**2.2 Value Chain Analysis
*Exhibit 08: Value chain analysis: Pharmaceuticals
*2.2.1 Research and development (R&D) and drug discovery
*2.2.2 Integration and product development
*2.2.3 Manufacturing
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Support services
*2.2.7 Innovation
***3. Market Sizing
**3.1 Market definition
*Exhibit 09: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 10: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*3.4.1Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 11: Global - Market size and forecast 2021 - 2026 (million $)
*Exhibit 12: Global market: Year-over-year growth 2021 - 2026 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 13: Five forces analysis 2021 - 2026
**4.2 Bargaining power of buyers
*Exhibit 14: Bargaining power of the buyer
**4.3 Bargaining power of suppliers
*Exhibit 15: Bargaining power of the supplier
**4.4 Threat of new entrants
*Exhibit 16: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 17: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 18: Threat of rivalry
**4.7 Market condition
*Exhibit 19: Market condition - Five forces 2021
***5. Market Segmentation by Type
**5.1 Market segments
*Exhibit 20 : Type- Market share 2020-2025 (%)
**5.2 Comparison by Type
*Exhibit 21: Comparison by Type
**5.3 Biologics - Market size and forecast 2021-2026
*Exhibit 22: Biologics - Market size and forecast 2021-2026 ($ billion)
*Exhibit 23: Biologics - Year-over-year growth 2021-2026 (%)
**5.4 Small molecules - Market size and forecast 2021-2026
*Exhibit 24: Small molecules - Market size and forecast 2021-2026 ($ billion)
*Exhibit 25: Small molecules- Year-over-year growth 2021-2026 (%)
**5.5 Market opportunity by Type
*Exhibit 26: Market opportunity by Type
***6 Market Segmentation by Route of administration
**6.1 Market segments
*Exhibit 27: Route of administration - Market share 2021-2026 (%)
**6.2 Comparison by Route of administration
*Exhibit 28: Comparison by Route of administration
**6.3 Parenteral - Market size and forecast 2021-2026
*Exhibit 29: Parenteral - Market size and forecast 2021-2026 ($ billion)
*Exhibit 30: Parenteral - Year-over-year growth 2021-2026 (%)
**6.4 Oral - Market size and forecast 2021-2026
*Exhibit 31: Oral - Market size and forecast 2021-2026 ($ billion)
*Exhibit 32: Oral - Year-over-year growth 2021-2026 (%)]
**6.5 Market opportunity by Route of administration
*Exhibit 33: Market opportunity by Route of administration
***7. Customer landscape
*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
*Exhibit 34: Customer landscape
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Strong pipeline
*8.1.2 Rising prevalence of multiple sclerosis
*8.1.3 Disease-modifying therapies
**8.2 Market challenges
*8.2.1 High cost of drugs
*8.2.2 Stringent regulatory guidelines
*8.2.3 Challenges in the diagnosis of multiple sclerosis
*Exhibit 35: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Rising strategic alliance and partnership among vendors
*8.3.2 Rising product approval
*8.3.3 Stem cell treatment for multiple sclerosis
***9. Vendor Landscape
**9.1 Overview
*Exhibit 36: Vendor landscape
**9.2 Landscape disruption
*Exhibit 37: ?Landscape disruption?
*Exhibit 38: Industry Risk
**9.3 Competitive Scenario
***10. Vendor Analysis
**10.1 Vendors Covered
*Exhibit 39: Vendor Landscape
**10.2 Market positioning of vendors
*Exhibit 40: ?Market positioning of vendors?
**10.3 Bayer AG
*Exhibit 41: Bayer AG - Overview
*Exhibit 42: Bayer AG - Business segments
*Exhibit 43: Bayer AG - Key news
*Exhibit 44: Bayer AG - Key offerings
*Exhibit 45: Bayer AG - Segment focus
**10.4 Biogen Inc.
*Exhibit 46: Biogen Inc. - Overview
*Exhibit 47: Biogen Inc. - Product and service
*Exhibit 48: Biogen Inc. - Key news
*Exhibit 49: Biogen Inc. - Key offerings
**10.5 Bristol Myers Squibb Co.
*Exhibit 50: Bristol Myers Squibb Co. - Overview
*Exhibit 51: Bristol Myers Squibb Co. - Product and service
*Exhibit 52: Bristol Myers Squibb Co. - Key news
*Exhibit 53: Bristol Myers Squibb Co. - Key offerings
**10.6 F. Hoffmann La Roche Ltd.
*Exhibit 54: F. Hoffmann La Roche Ltd. - Overview
*Exhibit 55: F. Hoffmann La Roche Ltd. - Business segments
*Exhibit 56: F. Hoffmann La Roche Ltd. - Key news
*Exhibit 57: F. Hoffmann La Roche Ltd. - Key offerings
*Exhibit 58: F. Hoffmann La Roche Ltd. - Segment focus
**10.7 Johnson and Johnson Inc.
*Exhibit 59: Johnson and Johnson Inc. - Overview
*Exhibit 60: Johnson and Johnson Inc. - Business segments
*Exhibit 61: Johnson and Johnson Inc. - Key news
*Exhibit 62: Johnson and Johnson Inc. - Key offerings
*Exhibit 63: Johnson and Johnson Inc. - Segment focus
**10.8 Novartis AG
*Exhibit 64: Novartis AG - Overview
*Exhibit 65: Novartis AG - Business segments
*Exhibit 66: Novartis AG - Key news
*Exhibit 67: Novartis AG - Key offerings
*Exhibit 68: Novartis AG - Segment focus
**10.9 Pfizer Inc.
*Exhibit 69: Pfizer Inc. - Overview
*Exhibit 70: Pfizer Inc. - Product and service
*Exhibit 71: Viatris Inc. - Key news
*Exhibit 72: Pfizer Inc. - Key offerings
**10.10 Sanofi SA
*Exhibit 73: Sanofi SA - Overview
*Exhibit 74: Sanofi SA - Business segments
*Exhibit 75: Sanofi SA - Key news
*Exhibit 76: Sanofi SA - Key offerings
*Exhibit 77: Sanofi SA - Segment focus
**10.11 Teva Pharmaceutical Industries Ltd.
*Exhibit 78: Teva Pharmaceutical Industries Ltd. - Overview
*Exhibit 79: Teva Pharmaceutical Industries Ltd. - Business segments
*Exhibit 80: Teva Pharmaceutical Industries Ltd. - Key news
*Exhibit 81: Teva Pharmaceutical Industries Ltd. - Key offerings
*Exhibit 82: Teva Pharmaceutical Industries Ltd. - Segment focus
**10.12 Viatris Inc.
*Exhibit 83: Viatris Inc. - Overview
*Exhibit 84: Viatris Inc. - Business segments
*Exhibit 85: Viatris Inc. - Key news
*Exhibit 86: Viatris Inc. - Key offerings
*Exhibit 87: Viatris Inc. - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 ????Objectives
*11.1.3 ????Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 88: ?Currency conversion rates for US$?
**11.3 Research Methodology
*Exhibit 89: ?Research Methodology
*Exhibit 90: ??Validation techniques employed for market sizing?
*Exhibit 91: ??Information sources
**11.4 List of abbreviations
*Exhibit 92: List of abbreviations
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.